| Two-component Radiology-guided Autonomous Cascade Engine (TRACE) (NCT07651644) | Liaoning Cancer Hospital & Institute | 2026-06-18 |
| Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology (NCT07161453) | Liaoning Cancer Hospital & Institute | 2025-09-30 |
| Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery (NCT07149181) | Liaoning Cancer Hospital & Institute | 2025-08-31 |
| Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer (NCT07132528) | Liaoning Cancer Hospital & Institute | 2025-08-31 |
| Optimal Application Timing of ADC Drugs for Advanced Breast Cancer (NCT07657130) | Liaoning Cancer Hospital & Institute | 2025-07-01 |
| Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC (NCT06908733) | Liaoning Cancer Hospital & Institute | 2025-03-31 |
| Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma (NCT06764251) | Liaoning Cancer Hospital & Institute | 2024-12-30 |
| Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations (NCT06299371) | Liaoning Cancer Hospital & Institute | 2024-04-15 |
| Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery (NCT06109454) | Liaoning Cancer Hospital & Institute | 2024-03-21 |
| Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors (NCT05887726) | Liaoning Cancer Hospital & Institute | 2023-08-01 |
| Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases (NCT05774964) | Liaoning Cancer Hospital & Institute | 2023-03-15 |
| Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection (NCT05720559) | Liaoning Cancer Hospital & Institute | 2023-03-01 |
| AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer (NCT05244993) | Liaoning Cancer Hospital & Institute | 2022-07-01 |
| Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer (NCT06305702) | Liaoning Cancer Hospital & Institute | 2022-07-01 |
| Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors (NCT05191914) | Liaoning Cancer Hospital & Institute | 2022-02-07 |
| Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma (NCT05132985) | Liaoning Cancer Hospital & Institute | 2022-01-01 |
| Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer (NCT05047848) | Liaoning Cancer Hospital & Institute | 2021-08-18 |
| To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment (NCT05688306) | Liaoning Cancer Hospital & Institute | 2020-09-02 |
| Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer (NCT03932526) | Liaoning Cancer Hospital & Institute | 2019-06-24 |
| Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients (NCT03815474) | Liaoning Cancer Hospital & Institute | 2019-05-20 |
| Irinotecan for Advanced and Metastatic Breast Cancer (NCT03562390) | Liaoning Cancer Hospital & Institute | 2017-04-01 |
| A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer (NCT02030678) | Liaoning Cancer Hospital & Institute | 2014-09-01 |
| Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer (NCT01763450) | Liaoning Cancer Hospital & Institute | 2012-09-01 |